Active, not recruiting

3

250

Europe, Canada, Japan, US, RoW

LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

08/23

05/27

Active, not recruiting

3

250

Europe, Japan, US, RoW

Pirtobrutinib, LOXO-305, LY3527727, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

Recruiting

2a

76

Europe

Inotuzumab Ozogamicin (IO)

Gruppo Italiano Malattie EMatologiche dell'Adulto

Acute Lymphoid Leukemia

11/22

11/22

Recruiting

2

440

Europe, RoW

Allogeneic Stem Cell Transplantation

Universitätsklinikum Hamburg-Eppendorf, DKMS Stiftung Leben Spenden, Clinical Trial Center North (CTC North GmbH & Co. KG)

Acute Myeloid Leukemia in Remission, Acute Lymphoblastic Leukemia in Remission, Myelodysplastic Syndromes

11/22

11/24

2

Europe

tagraxofusp

Acute Myeloid Leukemia

Recruiting

2

32

Europe

Ponatinib

Gruppo Italiano Malattie EMatologiche dell'Adulto, Incyte Biosciences International Sàrl, Docteur-Yersin 12, 1110 Morges, Switzerland, FONDAZIONE GIMEMA

Chemotherapy, Leukemia, Acute Lymphoblastic

02/25

07/28

Active, not recruiting

2

28

Europe

Obinutuzumab 25 MG/ML [Gazyva], Atezolizumab 60 MG/ML [Tecentriq], Venetoclax Oral Tablet

Niguarda Hospital

CLL Transformation

09/26

12/26

Terminated

1/2

63

Europe

NMS-03592088

Nerviano Medical Sciences

Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML)

08/24

08/24

Active, not recruiting

1

19

Europe

Blinatumomab Expanded T-cells (BET)

A.O. Ospedale Papa Giovanni XXIII

Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia

11/21

11/22

Recruiting

1

20

Europe

Mesenchymal Stromal Cells

Monia Lorini, Mario Negri Institute for Pharmacological Research

Liver Transplant Rejection

10/24

10/25

Recruiting

N/A

319

Europe

Ropeginterferon alfa-2b, Besremi

FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS

Polycythemia Vera

09/26

12/26

Recruiting

N/A

104

Europe

Venetoclax plus HMA

Gruppo Italiano Malattie EMatologiche dell'Adulto

Acute Myeloid Leukemia

12/22

12/23

Recruiting

N/A

32

Europe

bone marrow and/or peripheral blood samples withdrawal

Gruppo Italiano Malattie EMatologiche dell'Adulto

T Acute Lymphoblastic Leukemia, Early T Acute Lymphoblastic Leukemia, T-lymphoblastic Lymphoma, Etp All

05/24

05/24

Not yet recruiting

N/A

100

Europe

Gruppo Italiano Malattie EMatologiche dell'Adulto

VEXAS

02/25

06/25

Recruiting

N/A

1500

Europe

"novel" MAB (alone or in combination)

Fondazione Italiana Linfomi - ETS, Roche Pharma AG

Non-Hodgkin Lymphoma, B-cell

10/38

10/38

Active, not recruiting

3

245

Europe, Canada, Japan, US, RoW

Ponatinib, Iclusig, Imatinib, Gleevec, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone

Takeda

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

08/22

07/27

Recruiting

3

414

Europe

Gemtuzumab Ozogamicin

Gruppo Italiano Malattie EMatologiche dell'Adulto, Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus, Pfizer S.R.L.

Acute Myeloid Leukemia

04/25

04/27

Active, not recruiting

3

897

Europe, RoW

Ibrutinib, Imbruvica, Venetoclax, ABT-199, Venclyxto, Obinutuzumab, GA101, Gazyvaro

German CLL Study Group, Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Nordic CLL Study Group (NCLLSG), Swiss Group for Clinical Cancer Research (SAKK), Cancer Trials Ireland, Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA), Grupo Español de Leucemia Linfocítica Crónica (GELLC), The Israeli CLL Study Group (ICLLSG), Janssen Pharmaceutica N.V., Belgium, AbbVie, Hoffmann-La Roche

Chronic Lymphoid Leukemia

09/27

09/27

Recruiting

3

602

Europe

Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), R-Benda, R-bendamustine, Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A), R-CHOP, Immunochemotherapy regimen: R-CHOP (Arm B), Immunochemotherapy regimen: G-bendamustine (Arm A), G-Benda, Immunochemotherapy regimen: G-bendamustine (Arm B), Immunochemotherapy regimen: G-CHOP (Arm A), G-CHOP, Immunochemotherapy regimen: G-CHOP (Arm B), Immunochemotherapy regimen: G-CVP (Arm A), G-CVP, Immunochemotherapy regimen: G-CVP (Arm B)

Fondazione Italiana Linfomi - ETS

Follicular Lymphoma

07/28

07/30

Active, not recruiting

2

67

Europe

Ponatinib

Gruppo Italiano Malattie EMatologiche dell'Adulto, Incyte Biosciences International Sàrl, Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus

Philadelphia-Positive ALL, Acute Lymphoblastic Leukemia, in Relapse

11/24

11/24

Active, not recruiting

2

149

Europe

Chemotherapy + Blinatumomab

Gruppo Italiano Malattie EMatologiche dell'Adulto

Acute Lymphoid Leukemia, Philadelphia Chromosome-Negative B-Cell Precursor

02/24

02/24

Recruiting

N/A

250

Europe

Ospedale di Circolo - Fondazione Macchi

SARS-CoV-2 Infection, Hematological Malignancies

10/22

10/22

Recruiting

N/A

60

Europe

Dasatinib and blinatumomab

Gruppo Italiano Malattie EMatologiche dell'Adulto

Acute Lymphoblastic Leukemia

05/24

05/24

Active, not recruiting

2

60

Europe

Total therapy approach

Gruppo Italiano Malattie EMatologiche dell'Adulto

ALL Ph Positive

10/14

12/20

Completed

2

77

Europe

Venetoclax, Rituximab

Gruppo Italiano Malattie EMatologiche dell'Adulto

Chronic Myeloid Leukemia

09/21

05/23

Completed

1

6

Europe

Autologous NK cells infusions

Gruppo Italiano Malattie EMatologiche dell'Adulto

Acute Lymphoblastic Leukemia, Complete Hematologic Remission (CHR), Persistent/Recurrent Minimal Residual Disease (MRD)

11/21

11/21